Xiaoyan Lin

6.0k total citations · 1 hit paper
79 papers, 1.1k citations indexed

About

Xiaoyan Lin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Xiaoyan Lin has authored 79 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 16 papers in Surgery. Recurrent topics in Xiaoyan Lin's work include Gastric Cancer Management and Outcomes (18 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Colorectal Cancer Treatments and Studies (11 papers). Xiaoyan Lin is often cited by papers focused on Gastric Cancer Management and Outcomes (18 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Colorectal Cancer Treatments and Studies (11 papers). Xiaoyan Lin collaborates with scholars based in China, United States and Singapore. Xiaoyan Lin's co-authors include Weijia Fang, Shukui Qin, Jianping Xiong, Yuxian Bai, Enxiao Li, Jianjun Zou, Xiaohong Chen, Linna Wang, Zhenggang Ren and Xiaoli Chai and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Xiaoyan Lin

74 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

2020 418 citations Weijia Fang, Xiaoyan Lin et al. profile →

Peers

Countries citing papers authored by Xiaoyan Lin

Since Specialization

Citations

This map shows the geographic impact of Xiaoyan Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoyan Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoyan Lin more than expected).

Fields of papers citing papers by Xiaoyan Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoyan Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoyan Lin. The network helps show where Xiaoyan Lin may publish in the future.

Co-authorship network of co-authors of Xiaoyan Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoyan Lin. A scholar is included among the top collaborators of Xiaoyan Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoyan Lin. Xiaoyan Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Risk factors and predictive models for secondary hemorrhage in pediatric coblation tonsillectomy 2025 ·International Journal of Pediatric Otorhinolaryngology ·Bin Xu, (unknown), Yong Fu, (unknown), Lulu Yu, Yue Han, Xiaoyan Lin, (unknown)	0
2	Development and evaluation of a comprehensive Patient for Medication Safety (PFMS) intervention programme to improve participation in medication safety behaviours among older adults with chronic disease during hospital-to-home transition: a pilot randomized controlled trial 2025 ·BMC Geriatrics ·Wenshuai Xu, Xiaoyan Lin, (unknown), Yupeng Ren, (unknown), (unknown)	0
3	Sequential activation of ERα-AMPKα signaling by the flavonoid baicalin down-regulates viral HNF-dependent HBV replication 2024 ·Acta Pharmacologica Sinica ·(unknown), (unknown), (unknown), Weiming Xu, Xiaoyan Lin, Yingqi Zhu, Haiyan Zhu, Xian Zeng, Zhengguo Cao, Wei Zhou, Hai Huang, Xunlong Shi	2
4	Participation in medication safety of older-adult patients with chronic disease during the transition from hospital to home: a descriptive qualitative study 2024 ·BMC Geriatrics ·Xiaoyan Lin, Wenshuai Xu, (unknown)	1
5	Simple Sitting Baduanjin mind-body exercise: randomized controlled trial protocol for advanced cancer patients with the fatigue-sleep disturbance symptom cluster 2024 ·BMC Complementary Medicine and Therapies ·(unknown), Xiaoyan Lin, (unknown), Jianwei Zheng, Huimin Xiao	2
6	Involvement in medication safety behaviors among older people with chronic diseases: systematic review of intervention studies 2024 ·BMC Geriatrics ·Wenshuai Xu, Xiaoyan Lin, (unknown), Yupeng Ren, (unknown), (unknown)	1
7	A case of cardiac undifferentiated pleomorphic sarcoma in late pregnancy: A case report 2024 ·SHILAP Revista de lepidopterología ·(unknown), Xiaoyan Lin, (unknown)	0
8	Developing a Sitting Simple Baduanjin program for advanced cancer patients with the fatigue-sleep disturbance symptom cluster: A feasibility study 2024 ·Palliative & Supportive Care ·(unknown), (unknown), (unknown), Xiaoyan Lin, Jianwei Zheng, Huimin Xiao	0
9	Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors. 2024 ·Journal of Clinical Oncology ·Yuxiang Ma, (unknown), (unknown), (unknown), Yanqiu Zhao, Yubiao Guo, Gang Wu, (unknown), Xiaoqing Yu, Fangfang Gao, Ruiguang Zhang, Jian Fang, Xiaoyan Lin, Guanglin Liu, (unknown), (unknown), (unknown), Dajun Yang, Li Zhang, Yifan Zhai	1
10	Incidence, trend and risk factors associated with suicide among patients with malignant intracranial tumors: a surveillance, epidemiology, and end results analysis 2022 ·International Journal of Clinical Oncology ·(unknown), Pingping Jiang, Peiyu Zhang, Xiaoping Lin, (unknown), (unknown), Xiaoyan Lin, (unknown), Yu Yang, Xiaobing Jiang, Zhongping Chen, Yonggao Mou, De‐Pei Li, Ke Sai	3
11	The Effect of Low-Dose Chemotherapy on the Tumor Microenvironment and its Antitumor Activity Combined with Anti-PD-1 Antibody 2022 ·Immunotherapy ·(unknown), Hao Chen, (unknown), Jianwei Zheng, Qin Liu, (unknown), Xinli Wang, Xiaoyan Lin	8
12	Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics 2022 ·Anti-Cancer Drugs ·(unknown), (unknown), (unknown), (unknown), Lei Liu, Xiaoying Xu, Hongjing Liu, Jingliang Wang, (unknown), Wei Xu, Shuping Yang, (unknown), Xiaotian Yuan, Xiaoyan Lin, Fanghua Qi, Guobin Fu	6
13	Prevalence and Genetic Analysis of β-Thalassemia in the Dali Bai Autonomous Prefecture of the Yunnan Province, China 2022 ·Genetic Testing and Molecular Biomarkers ·(unknown), (unknown), Wei Zhang, (unknown), (unknown), Hui Su, Xiaoyan Lin, Jinying Yuan, Yan Wang, (unknown), (unknown)	2
14	Factors Associated with Behaviors Toward End-of-life Care Among Chinese Oncology Nurses: A Cross-Sectional Study 2021 ·Asian Nursing Research ·Xiaoyu Wu, (unknown), Yiheng Zhang, Xiaoyan Lin, Meng Zhang, (unknown), Meifen Zhang	6
15	PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer 2021 ·International Immunopharmacology ·(unknown), (unknown), (unknown), (unknown), Jianwei Zheng, Qing Liu, Bing Du, (unknown), Xiaoyan Lin	20
16	Knockdown of Forkhead box A1 suppresses the tumorigenesis and progression of human colon cancer cells through regulating the phosphatase and tensin homolog/Akt pathway 2020 ·Journal of International Medical Research ·Jie Pan, Zongbin Xu, Meifang Xu, Xiaoyan Lin, (unknown), (unknown)	4
17	Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study 2020 ·Advances in Therapy ·(unknown), Hao Chen, Jianwei Zheng, (unknown), (unknown), Qing Liu, (unknown), Xinli Wang, (unknown), (unknown), (unknown), (unknown), Xiaoyan Lin	4
18	Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China 2020 ·BMC Cancer ·Rui‐Hua Xu, Wei Wang, Bo Zhu, Xiaoyan Lin, Dong Ma, Lingjun Zhu, Qingchuan Zhao, Yongzhan Nie, (unknown), Qi Li, Weijia Fang, Hongyan Li, Ning Wang, (unknown), Cike Peng, (unknown), Lin Shen	24
19	Development and Testing of a Mobile App for Pain Management Among Cancer Patients Discharged From Hospital Treatment: Randomized Controlled Trial 2019 ·JMIR mhealth and uhealth ·Jing Yang, (unknown), (unknown), (unknown), Xiaoyan Lin, Zhijian Hu, (unknown), Bijuan Lin, (unknown), (unknown), (unknown), (unknown), (unknown)	56
20	Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial 2019 ·BMJ Open ·Mengxia Zhang, Zheng‐Xiang Li, (unknown), Guoxian Guan, Xiaoyan Lin, Xiaodong Wu, Pan Chi, Benhua Xu	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact